In a recent publication it was suggested that radiographic progression-free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC) was highly consistent and highly associated with overall survival. This reproducible quantitative find could have implications for the interim measurement of treatment response in future studies, according to Dr. Michael J. Morris of Memorial Sloan Kettering Cancer Center, New York, and his colleagues.
Dr. Morris points to the Cougar-Abiraterone Acetate Study 302 (COU-AA-302), a randomized, placebo-controlled phase III study of 1,088 men with mCRPC, where radiographic progression-free survival (rPFS) which was defined as the time from randomization of the subjects to the first occurrence of progression was highly positively associated with overall survival.
Dr. Morris said, “There has long been a need to develop additional time-to-event endpoints short of